10-Q: Firefly Neuroscience Q3 Revenue Soars, But Losses Widen

Firefly Neuroscience reported a significant revenue increase in Q3 2025 driven by the Evoke acquisition, yet net losses expanded due to derivative fair value changes and an intangible asset impairment.

Summary

• Revenue for the three months ended September 30, 2025, increased by 1,076% to $388 thousand, up from $33 thousand in the prior year, primarily due to the acquisition of Evoke Neuroscience.
• Nine-month revenue for 2025 surged by 1,227% to $730 thousand, compared to $55 thousand in 2024.
• Gross profit for Q3 2025 was $146 thousand, with a gross profit margin of 60% excluding an $85 thousand inventory adjustment.
• Operating expenses decreased in R&D (57% to $378 thousand) and S&M (39% to $265 thousand) for Q3 2025, largely due to reduced equity vesting and consultant use.
• General and administration expenses decreased by 33% to $2,007 thousand in Q3 2025, mainly from lower legal fees related to the August 2024 merger.
• A $152 thousand impairment loss on intangible assets was recognized in Q3 2025 due to a strategic shift post-Evoke acquisition.
• Net loss for Q3 2025 was $(2,639) thousand, an improvement from $(4,289) thousand in Q3 2024.
• However, the nine-month net loss for 2025 significantly widened to $(17,402) thousand from $(6,675) thousand in 2024, primarily due to a $9,369 thousand change in derivative fair value and a $1,353 thousand loss on settlement of a convertible promissory note.
• Cash and cash equivalents increased to $4,325 thousand as of September 30, 2025, from $1,810 thousand at December 31, 2024.
• Net cash used in operating activities increased by 29% to $(6,389) thousand for the nine months ended September 30, 2025.
• The company acquired Evoke Neuroscience, Inc. on April 30, 2025, for $3,000 thousand in cash and 857,142 shares of common stock valued at $2,743 thousand, plus a contingent earn-out of $478 thousand.
• Material weaknesses in internal controls over financial reporting were identified, specifically in IT General Controls and segregation of duties, with a remediation plan targeting Q1 2026 completion.

Sentiment

Score: 3

Explanation: While revenue growth is strong due to acquisition, the significant increase in net loss, substantial cash burn from operations, and identified material weaknesses in internal controls, coupled with the 'going concern' warning, indicate a highly challenging financial position. The reliance on future capital raises for continued operations adds to the negative sentiment.

Positives

• Significant revenue growth: Q3 2025 revenue increased by 1,076% to $388 thousand, and nine-month revenue increased by 1,227% to $730 thousand, largely driven by the Evoke Neuroscience acquisition.
• Improved gross profit margin: Excluding an $85 thousand inventory adjustment, the gross profit margin for Q3 2025 would have been 60%, and 75% for the nine months ended September 30, 2025.
• Reduced operating expenses in R&D and S&M: Q3 2025 R&D expenses decreased by 57% to $378 thousand, and S&M expenses decreased by 39% to $265 thousand, reflecting cost management and reduced consultant use.
• Increased cash balance: Cash and cash equivalents grew to $4,325 thousand as of September 30, 2025, from $1,810 thousand at December 31, 2024, supported by financing activities.
• Successful capital raises: The company secured $1,200 thousand from a June 2025 Units Offering and $1,643 thousand from a March 2025 Units Offering, alongside $8,825 thousand from warrant exercises.

Negatives

• Substantial net loss: The nine-month net loss for 2025 significantly widened to $(17,402) thousand from $(6,675) thousand in 2024.
• Significant non-cash losses: A $9,369 thousand loss from the change in derivative fair value and a $1,353 thousand loss on settlement of a convertible promissory note heavily impacted the nine-month net loss.
• Intangible asset impairment: A $152 thousand impairment charge was recorded for capitalized software development costs due to a change in strategic direction post-acquisition.
• Increased cash burn from operations: Net cash used in operating activities increased by 29% to $(6,389) thousand for the nine months ended September 30, 2025.
• Accumulated deficit: The company has an accumulated deficit of $108,896 thousand as of September 30, 2025, indicating a history of losses.
• Going concern doubt: Management acknowledges substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Risks

• Fluctuation and volatility in the market price of common stock due to market, industry, economic, political, and general market conditions.
• Ability to continue as a going concern, given recurring losses and negative cash flows from operations.
• Impact of dilution on stockholders from future issuances of additional equity securities.
• Ability to realize the intended benefits of the WaveDancer merger and the Evoke Neuroscience acquisition.
• Potential for litigation or other proceedings in the future.
• Risk of delisting from the Nasdaq Capital Market or failure for an active trading market to develop.
• Availability of and ability to obtain sufficient funding to conduct planned operations and realize potential profits.
• Limited operating history, making it difficult to evaluate future prospects.
• Complexity of the regulatory landscape and challenges in maintaining regulatory approval for products (e.g., FDA-510(k) cleared BNA and Evox System).
• Dependence on third parties for various aspects of the business.
• Challenges with products achieving market acceptance and the impact of product pricing.
• Ability to obtain, maintain, and protect trade secrets or other proprietary rights, operate without infringing on others' rights, and prevent infringement.
• Ability to maintain adequate cybersecurity and information systems, especially concerning PHI and clinical data.
• Reliance on machine learning models for EEG/ERP interpretation, with risks related to training data diversity, ongoing monitoring, generalizability, and model drift.
• Evolving regulatory guidance, including the FDA's approach to AI/ML-enabled medical devices, and payer expectations, which could impact timelines and costs.
• Potential adverse effects from public health crises, changes in economic and trade policies, and geopolitical events such as the ongoing war between Israel and Hamas, particularly impacting employees in Israel.

Future Outlook

Management expects to continue incurring negative cash flows from operations as it integrates the Evoke and BNA products and expands its sales organization. Achieving profitability beyond the next 12 months depends on the successful commercialization of the combined product portfolio. The company anticipates significant costs for continued product development, commercialization, and distribution, requiring substantial additional capital through equity, debt financing, or other sources. There is no assurance that such financing will be available on commercially reasonable terms or at all.

Management Comments

• Management has a reasonable expectation that the Company can continue raising additional capital to continue in operational existence for the foreseeable future.
• Management is committed to the remediation of the material weaknesses in internal controls, which began in Q1 2025 and will continue into the remainder of 2025, with a projected remediation date of Q1 2026.

Industry Context

Firefly Neuroscience operates in the rapidly evolving neuroscientific solutions market, leveraging AI and machine learning for brain health outcomes. The acquisition of Evoke Neuroscience expands its hardware and software offerings, positioning it to enhance neurological assessments and tailor personalized treatment plans. The company aims to capitalize on the clinical utility of EEG technology, which has historically faced adoption challenges due to interpretation complexity. By providing objective, data-driven insights and establishing a baseline for brain function, Firefly seeks to differentiate itself. Its strategy involves collaborations with pharmaceutical companies for drug research and clinical trials, alongside direct engagement with healthcare professionals. The industry is characterized by increasing reliance on AI/ML models, evolving regulatory landscapes (e.g., FDA guidance for AI/ML medical devices), and the need for robust cybersecurity for handling sensitive patient data.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The company's focus on AI-driven EEG/ERP analysis for mental and neurological disorders positions it in a niche within the broader medical device and diagnostics market. Direct comparisons would require detailed competitive analysis not present in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various claims, complaints, and legal actions in the normal course of business but is not currently aware of any pending litigation that it believes would have a material adverse effect on its operations or financial position.

Related Party Transactions

• NA No specific related party transactions were disclosed beyond standard compensation and equity issuances to directors and officers.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises and potential future equity issuances. The 'going concern' warning and substantial net losses pose a risk to investment value. However, revenue growth and strategic acquisitions could offer long-term potential if profitability is achieved.
• Employees: The acquisition of Evoke Neuroscience likely involved integration of new employees. The ongoing operations and strategic direction impact job security and opportunities, particularly for employees in Israel given geopolitical risks.
• Customers: The acquisition of Evoke Neuroscience expands product offerings (BNA and Evox System), potentially providing enhanced neurophysiological assessment tools. The focus on improving brain health outcomes and personalized treatment plans aims to benefit patients.
• Creditors: The 'going concern' warning and reliance on future capital raises indicate elevated risk for creditors, though recent financing activities have bolstered cash reserves temporarily.
• Suppliers: Continued operations and product development will maintain demand for supplies and services, but financial instability could pose payment risks.

Next Steps

• Integrate Evoke and BNA products.
• Continue to invest in the expansion of the sales organization.
• Further refine and optimize existing products and invest in their evolution.
• Evaluate opportunities and strategic partnerships to acquire or license other products and technologies.
• Generate revenue through the use of products by United States healthcare professionals and collaborations with pharmaceutical companies.
• Focus on targeted outreach and client engagement in the clinics segment, identifying key targets and scheduling meetings with decision-makers.
• Gather additional data through clinical deployments and clinical studies conducted by drug companies to discover new biomarkers and measure therapeutic impact.
• Remediate identified material weaknesses in IT General Controls and segregation of duties, with a projected completion date of Q1 2026.

Key Dates

Recommendation

Despite significant revenue growth driven by acquisition, the company faces substantial financial challenges, including a widening nine-month net loss of $(17.4) million, increased cash burn from operations, and an accumulated deficit of over $108 million. The explicit 'going concern' warning, coupled with identified material weaknesses in internal controls, signals high operational and financial risk. While strategic acquisitions and product development show potential, the heavy reliance on continuous capital raises and the lack of a clear path to profitability in the near term make the stock a high-risk investment. The non-cash losses from derivative fair value changes also highlight financial complexity. A seasoned investor would likely view these factors as significant red flags, suggesting a 'sell' or 'avoid' stance until there is clear evidence of sustainable profitability and resolution of internal control issues.

Keywords

Neuroscience, AIFF, Brain Network Analytics, EEG, ERP, Medical Devices, Artificial Intelligence, Machine Learning, Evoke Neuroscience, Biomarkers, Mental Health, Neurological Disorders, SEC Filing, 10-Q, Financial Results, Capital Raise, Going Concern